BioVaxys Company
.jpg)
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma.
Funding Status:
IPO
Total Funding:
$1 126 500
Headquarters:
New York, New York, United States
Last Funding Type:
Post-IPO Equity
Industry:
Women Cancer Treatment